A patient with oligometastatic hormone-sensitive prostate cancer who achieved long-term progression-free survival following cytoreductive radical prostatectomy and metastasectomy

Q4 Medicine

IJU Case Reports Pub Date : 2024-01-29 DOI:10.1002/iju5.12693

Daisuke Mamiya, Toshiki Kijima, Atsuko Takada-Owada, Hidetoshi Kokubun, Toshitaka Uematsu, Kohei Takei, Tsunehito Kambara, Kazuyuki Ishida, Hiroshi Taneichi, Takao Kamai

{"title":"A patient with oligometastatic hormone-sensitive prostate cancer who achieved long-term progression-free survival following cytoreductive radical prostatectomy and metastasectomy","authors":"Daisuke Mamiya, Toshiki Kijima, Atsuko Takada-Owada, Hidetoshi Kokubun, Toshitaka Uematsu, Kohei Takei, Tsunehito Kambara, Kazuyuki Ishida, Hiroshi Taneichi, Takao Kamai","doi":"10.1002/iju5.12693","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Oligometastatic prostate cancer can be well-controlled through combined local and metastasis-directed therapies. However, the effects of cytoreductive radical prostatectomy and metastasectomy remain unclear.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>A 52-year-old man presented with prostate cancer and isolated bone metastasis to the thoracic spine. Six months after neoadjuvant hormonal therapy, the patient underwent cytoreductive radical prostatectomy and total en bloc spondylectomy. The postoperative course was uneventful. Hormonal therapy was terminated 5 years after surgery, and no biochemical or radiological progression was observed at 7 years postoperatively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Although careful patient selection is necessary, cytoreductive radical prostatectomy and metastasectomy are effective treatments for well-selected patients with oligometastatic prostate cancer.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 2","pages":"165-168"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.12693","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Oligometastatic prostate cancer can be well-controlled through combined local and metastasis-directed therapies. However, the effects of cytoreductive radical prostatectomy and metastasectomy remain unclear.

Case presentation

A 52-year-old man presented with prostate cancer and isolated bone metastasis to the thoracic spine. Six months after neoadjuvant hormonal therapy, the patient underwent cytoreductive radical prostatectomy and total en bloc spondylectomy. The postoperative course was uneventful. Hormonal therapy was terminated 5 years after surgery, and no biochemical or radiological progression was observed at 7 years postoperatively.

Conclusion

Although careful patient selection is necessary, cytoreductive radical prostatectomy and metastasectomy are effective treatments for well-selected patients with oligometastatic prostate cancer.

Abstract Image

查看原文本刊更多论文

一名对激素敏感的寡转移性前列腺癌患者在接受前列腺癌根治性细胞切除术和转移灶切除术后获得了长期无进展生存期

导言通过局部和转移灶导向的联合疗法，可以很好地控制寡转移性前列腺癌。然而，前列腺癌根治性切除术和转移灶切除术的效果仍不明确。病例介绍一名 52 岁的男性患有前列腺癌，胸椎有孤立的骨转移灶。在接受新辅助激素治疗 6 个月后，患者接受了前列腺根治性切除术和全脊椎切除术。术后恢复顺利。术后 5 年终止了激素治疗，术后 7 年未观察到生化或放射学进展。结论虽然需要谨慎选择患者，但对于选择得当的寡转移性前列腺癌患者来说，细胞切除前列腺癌根治术和转移灶切除术是有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊